Literature DB >> 29797330

Human cytomegalovirus (HCMV)-specific T cell but not neutralizing or IgG binding antibody responses to glycoprotein complexes gB, gHgLgO, and pUL128L correlate with protection against high HCMV viral load reactivation in solid-organ transplant recipients.

Daniele Lilleri1, Paola Zelini1, Chiara Fornara1, Federica Zavaglio1, Teresa Rampino2, Laurent Perez3, Elisa Gabanti1, Giuseppe Gerna1,4.   

Abstract

Immune correlates of protection against human cytomegalovirus (HCMV) infection are still debated. This study aimed to investigate which arm of the immune response plays a major role in protection against HCMV infection in kidney transplant recipients (n = 40) and heart transplant recipients (n = 12). Overall, patients were divided into 2 groups: one including 37 patients with low viral load (LVL), and the other including 15 patients with high viral load (HVL). All LVL patients resolved the infection spontaneously, whereas HVL patients were all treated with one or more courses of antivirals. In HVL patients, viral DNAemia, which was more than 100 times higher than LVL, appeared and peaked at significantly earlier times, but disappeared much later than in LVL patients. During a 1-year follow-up, all LVL patients had levels of HCMV-specific CD4+ (and CD8+ ) T cells significantly higher than HVL patients. On the contrary, titers of neutralizing antibodies and enzyme-linked immunosorbent assay-IgG antibodies to gB, gHgLgO, and pentamer gHgLpUL128L were overlapping in the 2 patient groups. In conclusion, while a valid HCMV-specific T-cell response was detected in more than 90% of LVL patients, >90% of HVL patients lacked an adequate T-cell response. Antibody responses did not appear to be associated directly or indirectly with protection.
© 2018 Wiley Periodicals, Inc.

Entities:  

Keywords:  T-cell response; antibody response; high viral load (HVL); human cytomegalovirus (HCMV); low viral load (LVL); solid-organ transplant recipients (SOTR)

Mesh:

Substances:

Year:  2018        PMID: 29797330     DOI: 10.1002/jmv.25225

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  11 in total

1.  Immune Correlates of Protection Against Human Cytomegalovirus Acquisition, Replication, and Disease.

Authors:  Cody S Nelson; Ilona Baraniak; Daniele Lilleri; Matthew B Reeves; Paul D Griffiths; Sallie R Permar
Journal:  J Infect Dis       Date:  2020-03-05       Impact factor: 5.226

2.  Human Cytomegalovirus Glycoprotein B Nucleoside-Modified mRNA Vaccine Elicits Antibody Responses with Greater Durability and Breadth than MF59-Adjuvanted gB Protein Immunization.

Authors:  Cody S Nelson; Jennifer A Jenks; Norbert Pardi; Matthew Goodwin; Hunter Roark; Whitney Edwards; Jason S McLellan; Justin Pollara; Drew Weissman; Sallie R Permar
Journal:  J Virol       Date:  2020-04-16       Impact factor: 5.103

3.  Cell-to-Cell Spread Blocking Activity Is Extremely Limited in the Sera of Herpes Simplex Virus 1 (HSV-1)- and HSV-2-Infected Subjects.

Authors:  Elena Criscuolo; Matteo Castelli; Roberta A Diotti; Virginia Amato; Roberto Burioni; Massimo Clementi; Alessandro Ambrosi; Nicasio Mancini; Nicola Clementi
Journal:  J Virol       Date:  2019-05-15       Impact factor: 5.103

4.  Human cytomegalovirus (HCMV) long-term shedding and HCMV-specific immune response in pregnant women with primary HCMV infection.

Authors:  C Fornara; F Zavaglio; M Furione; A Sarasini; P d'Angelo; A Arossa; A Spinillo; D Lilleri; F Baldanti
Journal:  Med Microbiol Immunol       Date:  2022-08-12       Impact factor: 4.148

Review 5.  Antibodies to combat viral infections: development strategies and progress.

Authors:  Giuseppe Pantaleo; Bruno Correia; Craig Fenwick; Victor S Joo; Laurent Perez
Journal:  Nat Rev Drug Discov       Date:  2022-06-20       Impact factor: 112.288

Review 6.  Human Cytomegalovirus Congenital (cCMV) Infection Following Primary and Nonprimary Maternal Infection: Perspectives of Prevention through Vaccine Development.

Authors:  Giuseppe Gerna; Daniele Lilleri
Journal:  Vaccines (Basel)       Date:  2020-04-23

Review 7.  The CD4+ T Cell Response to Human Cytomegalovirus in Healthy and Immunocompromised People.

Authors:  Eleanor Y Lim; Sarah E Jackson; Mark R Wills
Journal:  Front Cell Infect Microbiol       Date:  2020-05-19       Impact factor: 5.293

Review 8.  Prevention of Congenital Cytomegalovirus Infection with Vaccines: State of the Art.

Authors:  Susanna Esposito; Giulia Chiopris; Giulia Messina; Tiziana D'Alvano; Serafina Perrone; Nicola Principi
Journal:  Vaccines (Basel)       Date:  2021-05-19

Review 9.  Utility of CMV-Specific Immune Monitoring for the Management of CMV in Solid Organ Transplant Recipients: A Clinical Update.

Authors:  Katya Prakash; Aditya Chandorkar; Kapil K Saharia
Journal:  Diagnostics (Basel)       Date:  2021-05-13

Review 10.  Virus-Like Particles and Nanoparticles for Vaccine Development against HCMV.

Authors:  Michela Perotti; Laurent Perez
Journal:  Viruses       Date:  2019-12-28       Impact factor: 5.048

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.